Retevmo – an inhibitor of all types of cancer
ADC评论
September 28, 2022
On September 21, 2022, Eli Lilly announced that the U.S. Food and Drug Administration (FDA) has accelerated approval of its precision oncology drug Retevmo (selpercatinib,
